The Filings Report

Abbott Laboratories

ABTNYSECIK 1800Healthcare / Drug Manufacturersfiscal year ends December74 quarters since 2007

Revenue, Q1 FY2026
$11.2B
+7.8% on Q1 FY2025
Net income
$1.1B
−18.7% on Q1 FY2025
Free cash flow
$916M
−1.8% on Q1 FY2025
Diluted EPS
$0.61
−19.7% on Q1 FY2025
Revenue, TTM
$45.1B
trailing four quarters
Net margin, TTM
13.9%
net income $6.3B
Free cash flow, TTM
$7.4B
$9.5B less $2.1B capex
Cash and equivalents
$6.8B
long-term debt $29.6B, Mar 31, 2026
Shares, 12-month change
+0.1%
1.74B shares, Mar 31, 2026
Buybacks, TTM
$793M
0.4% of market value
Dividends, TTM
$4.2B
2.3% of market value
Market value
$185.0B
at the close, buybacks

Latest quarter Q1 FY2026, filed April 29, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q1 FY2026, the quarter ended March 31, 2026, Abbott Laboratories reported revenue of $11.2B, +7.8% on Q1 FY2025, and net income of $1.1B (−18.7%). Operating margin was 12.0%. Free cash flow, operating cash flow less capital expenditures, was $916M ($1.3B less $399M). Diluted earnings per share were $0.61.

The last 16 quarters

Q2 FY2022 to Q1 FY2026, through the filing of April 29, 2026.

Revenue and net incomeRevenueNet income
$0$5B$10B$15BQ2'22, Revenue: $11.3BQ2'22, Net income: $2.0BQ2'22Q3'22, Revenue: $10.4BQ3'22, Net income: $1.4BQ3'22Q4'22, Revenue: $10.1BQ4'22, Net income: $1.0BQ4'22Q1'23, Revenue: $9.7BQ1'23, Net income: $1.3BQ1'23Q2'23, Revenue: $10.0BQ2'23, Net income: $1.4BQ2'23Q3'23, Revenue: $10.1BQ3'23, Net income: $1.4BQ3'23Q4'23, Revenue: $10.2BQ4'23, Net income: $1.6BQ4'23Q1'24, Revenue: $10.0BQ1'24, Net income: $1.2BQ1'24Q2'24, Revenue: $10.4BQ2'24, Net income: $1.3BQ2'24Q3'24, Revenue: $10.6BQ3'24, Net income: $1.6BQ3'24Q4'24, Revenue: $11.0BQ4'24, Net income: $9.2BQ4'24Q1'25, Revenue: $10.4BQ1'25, Net income: $1.3BQ1'25Q2'25, Revenue: $11.1BQ2'25, Net income: $1.8BQ2'25Q3'25, Revenue: $11.4BQ3'25, Net income: $1.6BQ3'25Q4'25, Revenue: $11.5BQ4'25, Net income: $1.8BQ4'25Q1'26, Revenue: $11.2BQ1'26, Net income: $1.1BQ1'26$0$5B$10B$15BQ2'22, Revenue: $11.3BQ2'22, Net income: $2.0BQ3'22, Revenue: $10.4BQ3'22, Net income: $1.4BQ3'22Q4'22, Revenue: $10.1BQ4'22, Net income: $1.0BQ1'23, Revenue: $9.7BQ1'23, Net income: $1.3BQ1'23Q2'23, Revenue: $10.0BQ2'23, Net income: $1.4BQ3'23, Revenue: $10.1BQ3'23, Net income: $1.4BQ3'23Q4'23, Revenue: $10.2BQ4'23, Net income: $1.6BQ1'24, Revenue: $10.0BQ1'24, Net income: $1.2BQ1'24Q2'24, Revenue: $10.4BQ2'24, Net income: $1.3BQ3'24, Revenue: $10.6BQ3'24, Net income: $1.6BQ3'24Q4'24, Revenue: $11.0BQ4'24, Net income: $9.2BQ1'25, Revenue: $10.4BQ1'25, Net income: $1.3BQ1'25Q2'25, Revenue: $11.1BQ2'25, Net income: $1.8BQ3'25, Revenue: $11.4BQ3'25, Net income: $1.6BQ3'25Q4'25, Revenue: $11.5BQ4'25, Net income: $1.8BQ1'26, Revenue: $11.2BQ1'26, Net income: $1.1BQ1'26

Net income losses drawn in red.

Free cash flow
$0$1B$2B$3BQ2'22, Free cash flow: $2.0BQ2'22Q3'22, Free cash flow: $2.3BQ3'22Q4'22, Free cash flow: $1.7BQ4'22Q1'23, Free cash flow: $763MQ1'23Q2'23, Free cash flow: $696MQ2'23Q3'23, Free cash flow: $1.3BQ3'23Q4'23, Free cash flow: $2.3BQ4'23Q1'24, Free cash flow: $627MQ1'24Q2'24, Free cash flow: $1.4BQ2'24Q3'24, Free cash flow: $2.1BQ3'24Q4'24, Free cash flow: $2.1BQ4'24Q1'25, Free cash flow: $933MQ1'25Q2'25, Free cash flow: $1.5BQ2'25Q3'25, Free cash flow: $2.3BQ3'25Q4'25, Free cash flow: $2.6BQ4'25Q1'26, Free cash flow: $916MQ1'26$0$1B$2B$3BQ2'22, Free cash flow: $2.0BQ3'22, Free cash flow: $2.3BQ3'22Q4'22, Free cash flow: $1.7BQ1'23, Free cash flow: $763MQ1'23Q2'23, Free cash flow: $696MQ3'23, Free cash flow: $1.3BQ3'23Q4'23, Free cash flow: $2.3BQ1'24, Free cash flow: $627MQ1'24Q2'24, Free cash flow: $1.4BQ3'24, Free cash flow: $2.1BQ3'24Q4'24, Free cash flow: $2.1BQ1'25, Free cash flow: $933MQ1'25Q2'25, Free cash flow: $1.5BQ3'25, Free cash flow: $2.3BQ3'25Q4'25, Free cash flow: $2.6BQ1'26, Free cash flow: $916MQ1'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$10B$20B$30BQ2'22, Cash and equivalents: $8.9BQ2'22, Long-term debt: $16.8BQ2'22Q3'22, Cash and equivalents: $9.6BQ3'22, Long-term debt: $15.3BQ3'22Q4'22, Cash and equivalents: $9.9BQ4'22, Long-term debt: $14.5BQ4'22Q1'23, Cash and equivalents: $9.2BQ1'23, Long-term debt: $14.6BQ1'23Q2'23, Cash and equivalents: $7.8BQ2'23, Long-term debt: $14.6BQ2'23Q3'23, Cash and equivalents: $6.7BQ3'23, Long-term debt: $14.5BQ3'23Q4'23, Cash and equivalents: $6.9BQ4'23, Long-term debt: $13.6BQ4'23Q1'24, Cash and equivalents: $6.3BQ1'24, Long-term debt: $12.6BQ1'24Q2'24, Cash and equivalents: $7.0BQ2'24, Long-term debt: $13.1BQ2'24Q3'24, Cash and equivalents: $7.6BQ3'24, Long-term debt: $12.8BQ3'24Q4'24, Cash and equivalents: $7.6BQ4'24, Long-term debt: $12.6BQ4'24Q1'25, Cash and equivalents: $6.5BQ1'25, Long-term debt: $12.7BQ1'25Q2'25, Cash and equivalents: $7.0BQ2'25, Long-term debt: $12.9BQ2'25Q3'25, Cash and equivalents: $7.5BQ3'25, Long-term debt: $11.6BQ3'25Q4'25, Cash and equivalents: $8.5BQ4'25, Long-term debt: $9.9BQ4'25Q1'26, Cash and equivalents: $6.8BQ1'26, Long-term debt: $29.6BQ1'26$0$10B$20B$30BQ2'22, Cash and equivalents: $8.9BQ2'22, Long-term debt: $16.8BQ3'22, Cash and equivalents: $9.6BQ3'22, Long-term debt: $15.3BQ3'22Q4'22, Cash and equivalents: $9.9BQ4'22, Long-term debt: $14.5BQ1'23, Cash and equivalents: $9.2BQ1'23, Long-term debt: $14.6BQ1'23Q2'23, Cash and equivalents: $7.8BQ2'23, Long-term debt: $14.6BQ3'23, Cash and equivalents: $6.7BQ3'23, Long-term debt: $14.5BQ3'23Q4'23, Cash and equivalents: $6.9BQ4'23, Long-term debt: $13.6BQ1'24, Cash and equivalents: $6.3BQ1'24, Long-term debt: $12.6BQ1'24Q2'24, Cash and equivalents: $7.0BQ2'24, Long-term debt: $13.1BQ3'24, Cash and equivalents: $7.6BQ3'24, Long-term debt: $12.8BQ3'24Q4'24, Cash and equivalents: $7.6BQ4'24, Long-term debt: $12.6BQ1'25, Cash and equivalents: $6.5BQ1'25, Long-term debt: $12.7BQ1'25Q2'25, Cash and equivalents: $7.0BQ2'25, Long-term debt: $12.9BQ3'25, Cash and equivalents: $7.5BQ3'25, Long-term debt: $11.6BQ3'25Q4'25, Cash and equivalents: $8.5BQ4'25, Long-term debt: $9.9BQ1'26, Cash and equivalents: $6.8BQ1'26, Long-term debt: $29.6BQ1'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q1 FY2026 filed April 29, 2026.

Abbott Laboratories income statement, quarterly
Millions of dollarsQ1 FY2026ended Mar 31, 2026filed Apr 29, 2026Q4 FY2025ended Dec 31, 2025filed Feb 20, 2026Q3 FY2025ended Sep 30, 2025filed Oct 29, 2025Q2 FY2025ended Jun 30, 2025filed Jul 30, 2025Q1 FY2025ended Mar 31, 2025filed Apr 30, 2025Q4 FY2024ended Dec 31, 2024filed Feb 21, 2025Q3 FY2024ended Sep 30, 2024filed Oct 31, 2024Q2 FY2024ended Jun 30, 2024filed Jul 31, 2024YoYQ1 FY2026vs Q1 FY2025
Revenue11,16411,45911,36911,14210,35810,97410,63510,377+7.8%
Cost of revenue4,8904,9225,0754,8544,4684,9424,6984,603+9.4%
Gross profit—————————
Research and development767735766725716749713698+7.1%
Selling, general and administrative3,7403,1293,0513,0913,0612,9072,8952,936+22.2%
Operating income1,3452,2512,0572,0521,6931,9111,8591,669−20.6%
Other income (expense)159134150137127154121(10)+25.2%
Pretax income1,4492,3582,1802,1501,7782,0301,9401,607−18.5%
Income tax372582536371453(7,199)294305−17.9%
Net income1,0771,7761,6441,7791,3259,2291,6461,302−18.7%
Diluted EPS ($)0.61—0.941.010.76—0.940.74−19.7%
Diluted shares (millions)1,747—1,7491,7511,747—1,7481,751—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q1 FY2026 filed April 29, 2026.

Abbott Laboratories balance sheet, quarterly
Millions of dollarsQ1 FY2026ended Mar 31, 2026filed Apr 29, 2026Q4 FY2025ended Dec 31, 2025filed Feb 20, 2026Q3 FY2025ended Sep 30, 2025filed Oct 29, 2025Q2 FY2025ended Jun 30, 2025filed Jul 30, 2025Q1 FY2025ended Mar 31, 2025filed Apr 30, 2025Q4 FY2024ended Dec 31, 2024filed Feb 21, 2025Q3 FY2024ended Sep 30, 2024filed Oct 31, 2024Q2 FY2024ended Jun 30, 2024filed Jul 31, 2024YoYQ1 FY2026vs Q1 FY2025
Cash and equivalents6,8038,5227,5116,9516,5327,6167,5586,987+4.1%
Short-term investments492417222331312351230232+57.7%
Total current assets25,50825,99624,83924,46823,15323,65623,80223,119+10.2%
Total assets110,42986,71384,18183,99981,44881,41474,35673,017+35.6%
Total current liabilities18,37716,49614,58213,43913,00414,15714,90213,760+41.3%
Long-term debt29,6389,89611,59612,93012,73612,62512,82513,139+132.7%
Total liabilities—————————
Stockholders’ equity52,06152,13050,95450,56548,81147,66439,79639,318+6.7%
Shares outstanding (millions)1,7421,7381,7391,7401,7401,7341,7341,740—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q1 FY2026 filed April 29, 2026.

Abbott Laboratories cash flow statement, quarterly
Millions of dollarsQ1 FY2026ended Mar 31, 2026filed Apr 29, 2026Q4 FY2025ended Dec 31, 2025filed Feb 20, 2026Q3 FY2025ended Sep 30, 2025filed Oct 29, 2025Q2 FY2025ended Jun 30, 2025filed Jul 30, 2025Q1 FY2025ended Mar 31, 2025filed Apr 30, 2025Q4 FY2024ended Dec 31, 2024filed Feb 21, 2025Q3 FY2024ended Sep 30, 2024filed Oct 31, 2024Q2 FY2024ended Jun 30, 2024filed Jul 31, 2024YoYQ1 FY2026vs Q1 FY2025
Operating cash flow1,3153,3152,7872,0471,4172,8682,7051,960−7.2%
Capital expenditures399689496502484720556533−17.6%
Free cash flow (CFO − capex)9162,6262,2911,5459332,1482,1491,427−1.8%
Depreciation and amortization—————————
Share repurchases18030230562803157513−35.7%
Dividends paid1,0981,0301,0311,0291,026958960961+7.0%

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 20, 2026.

Income statement

Abbott Laboratories income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 20, 2026FY2024ended Dec 31, 2024filed Feb 21, 2025FY2023ended Dec 31, 2023filed Feb 16, 2024FY2022ended Dec 31, 2022filed Feb 17, 2023FY2021ended Dec 31, 2021filed Feb 18, 2022FY2020ended Dec 31, 2020filed Feb 19, 2021FY2019ended Dec 31, 2019filed Feb 21, 2020FY2018ended Dec 31, 2018filed Feb 22, 2019FY2017ended Dec 31, 2017filed Feb 16, 2018FY2016ended Dec 31, 2016filed Feb 17, 2017FY2015ended Dec 31, 2015filed Feb 19, 2016FY2014ended Dec 31, 2014filed Feb 27, 2015FY2013ended Dec 31, 2013filed Feb 21, 2014FY2012ended Dec 31, 2012filed Feb 15, 2013FY2011ended Dec 31, 2011filed Feb 21, 2012FY2010ended Dec 31, 2010filed Feb 18, 2011FY2009ended Dec 31, 2009filed Feb 19, 2010FY2008ended Dec 31, 2008filed Aug 7, 2009FY2007ended Dec 31, 2007filed Aug 7, 2009
Revenue44,32841,95040,10943,65343,07534,60831,90430,57827,39020,85320,40520,24719,65719,05021,40735,16730,76529,52825,914
Cost of revenue19,31918,70617,97519,14218,53715,00313,23112,70612,4099,094—————————
Gross profit———————————————————
Research and development2,9422,8442,7412,8882,7422,4202,4402,3002,260——————————
Selling, general and administrative12,33211,69710,94911,24811,3249,6969,7659,7449,1826,7366,7856,5306,3726,7357,36510,3768,4068,4367,408
Operating income8,0536,8256,4788,3628,4255,3574,5323,6501,5643,0262,8672,5992,1331,3601,6296,0886,2365,6944,579
Other income (expense)5483764793212771031911391,413(786)281(14)321(119)621,375455(136)
Pretax income8,4667,0136,6648,3068,2114,9684,0772,8732,2311,4133,1832,5182,041(220)1,2365,7137,194——
Income tax1,942(6,389)9411,3731,1404973905391,87835057779753(457)1101,0871,4481,122863
Net income6,52413,4025,7236,9337,0714,4953,6872,3684771,4004,4232,2842,5765,9634,728————
Diluted EPS ($)3.727.643.263.913.942.502.061.330.270.942.921.491.623.723.012.963.693.122.31
Diluted shares (millions)1,7481,7481,7491,7641,7891,7861,7811,7701,7491,4831,5061,5271,5741,5921,5671,5561,5551,5611,560

Balance sheet

Abbott Laboratories balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 20, 2026FY2024ended Dec 31, 2024filed Feb 21, 2025FY2023ended Dec 31, 2023filed Feb 16, 2024FY2022ended Dec 31, 2022filed Feb 17, 2023FY2021ended Dec 31, 2021filed Feb 18, 2022FY2020ended Dec 31, 2020filed Feb 19, 2021FY2019ended Dec 31, 2019filed Feb 21, 2020FY2018ended Dec 31, 2018filed Feb 22, 2019FY2017ended Dec 31, 2017filed Feb 16, 2018FY2016ended Dec 31, 2016filed Feb 17, 2017FY2015ended Dec 31, 2015filed Feb 19, 2016FY2014ended Dec 31, 2014filed Feb 27, 2015FY2013ended Dec 31, 2013filed Feb 21, 2014FY2012ended Dec 31, 2012filed Feb 15, 2013FY2011ended Dec 31, 2011filed Feb 21, 2012FY2010ended Dec 31, 2010filed Feb 18, 2011FY2009ended Dec 31, 2009filed Feb 19, 2010FY2008ended Dec 31, 2008filed Aug 7, 2009FY2007ended Dec 31, 2007filed Aug 7, 2009
Cash and equivalents8,5227,6166,8969,8829,7996,8383,8603,8449,40718,6205,0014,0633,47510,8026,8133,6488,8094,1122,456
Short-term investments4173513832884503102802422031551,1243974,6234,3721,2851,8031,123968364
Total current assets25,99623,65622,67025,22424,23920,44115,66714,63220,14726,77614,15513,55619,24731,32323,76922,31823,31417,04314,043
Total assets86,71381,41473,21474,43875,19672,54867,88767,17376,25052,66641,24741,20742,93767,23560,27760,57452,58242,41939,714
Total current liabilities16,49614,15713,84115,48913,10511,90710,8639,0128,9126,6609,18610,4679,50713,28015,48017,26213,04911,5929,103
Long-term debt9,89612,62513,59914,52217,29618,52716,66119,3591,15020,6815,8713,3933,38818,08512,04012,52411,2668,7139,488
Total liabilities———————————————————
Stockholders’ equity52,13047,66438,60336,68635,80232,78431,08830,52430,89720,53821,21121,52625,17126,72124,44022,67723,14417,48017,779
Shares outstanding (millions)1,7381,7341,7351,7381,7631,7721,7631,7561,7461,7281,4731,5091,5431,5711,5721,5481,553——

Cash flow statement

Abbott Laboratories cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 20, 2026FY2024ended Dec 31, 2024filed Feb 21, 2025FY2023ended Dec 31, 2023filed Feb 16, 2024FY2022ended Dec 31, 2022filed Feb 17, 2023FY2021ended Dec 31, 2021filed Feb 18, 2022FY2020ended Dec 31, 2020filed Feb 19, 2021FY2019ended Dec 31, 2019filed Feb 21, 2020FY2018ended Dec 31, 2018filed Feb 22, 2019FY2017ended Dec 31, 2017filed Feb 16, 2018FY2016ended Dec 31, 2016filed Feb 17, 2017FY2015ended Dec 31, 2015filed Feb 19, 2016FY2014ended Dec 31, 2014filed Feb 27, 2015FY2013ended Dec 31, 2013filed Feb 21, 2014FY2012ended Dec 31, 2012filed Feb 15, 2013FY2011ended Dec 31, 2011filed Feb 21, 2012FY2010ended Dec 31, 2010filed Feb 18, 2011FY2009ended Dec 31, 2009filed Feb 19, 2010FY2008ended Dec 31, 2008filed Aug 7, 2009FY2007ended Dec 31, 2007filed Aug 7, 2009
Operating cash flow9,5668,5587,2619,58110,5337,9016,1366,3005,5703,2032,9663,6753,3249,3148,970————
Capital expenditures2,1712,2072,2021,7771,8852,1771,6381,3941,1351,1211,1101,0771,1451,7951,4911,0151,0891,2881,656
Free cash flow (CFO − capex)7,3956,3515,0597,8048,6485,7244,4984,9064,4352,0821,8562,5982,1797,5197,479————
Depreciation and amortization———————————————————
Share repurchases8931,2951,2273,7952,2994037182381175222,2372,1951,6052,364778678261,0821,059
Dividends paid4,1163,8363,5563,3093,2022,5602,2701,9741,8491,5391,4431,3428823,1832,9382,6712,4142,1741,959

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$47M
4 sales by 3 insiders; officers and directors $47M
Bought, twelve months
$4M
6 purchases by 4 insiders; officers and directors $4M
Sold, twelve months
$48M
11 sales by 7 insiders; officers and directors $48M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Sep 23, 2026Conroy Kevin TDirectortax withholding52,507$103.99$5M81,230Sep 25, 2026
Sep 2, 2026Mccoy John A. JR.VICE PRESIDENT AND CONTROLLERopen-market sale27$109.54$3K24,549Sep 3, 2026
Sep 1, 2026Mccoy John A. JR.VICE PRESIDENT AND CONTROLLERtax withholding52$110.36$6K24,576Sep 3, 2026
Sep 1, 2026Boudreau Philip PEVP AND CFOtax withholding388$110.36$43K70,784Sep 3, 2026
Aug 25, 2026Ford Robert BCHAIRMAN AND CEO, Directoroption exercise151,869$44.40$7M458,330Aug 27, 2026
Aug 25, 2026Ford Robert BCHAIRMAN AND CEO, Directoroption exercise246,963$59.94$15M705,293Aug 27, 2026
Aug 25, 2026Ford Robert BCHAIRMAN AND CEO, Directoropen-market sale218,535$115.57$25M486,758Aug 27, 2026
Aug 25, 2026Ford Robert BCHAIRMAN AND CEO, Directoropen-market sale180,297$116.19$21M306,461Aug 27, 2026
Aug 12, 2026Morrone Louis H.EXECUTIVE VICE PRESIDENTdiscretionaryindirect12$107.99$1K0Aug 13, 2026
Aug 11, 2026Morrone Louis H.EXECUTIVE VICE PRESIDENTopen-market sale5,850$109.83$643K70,724Aug 13, 2026
Jun 30, 2026Morrone Louis H.EXECUTIVE VICE PRESIDENTtax withholding269$92.71$25K76,574Jul 1, 2026
Jun 27, 2026Cushman Elizabeth C.EVP, GC AND SECRETARYtax withholding560$94.12$53K38,013Jun 29, 2026
May 7, 2026Stratton John GDirectoropen-market buy2,000$86.82$174K23,319Jun 18, 2026
Apr 28, 2026Moreland Mary KEXECUTIVE VICE PRESIDENTdiscretionaryindirect5,314$94.41$502K17,159Apr 29, 2026
Apr 27, 2026Starks Daniel JDirectoropen-market buy10,000$92.65$927K7MApr 28, 2026
Apr 24, 2026Conroy Kevin TDirectoraward2,286$0.00—133,737Apr 28, 2026
Apr 24, 2026Stratton John GDirectoraward2,286$0.00—21,319Apr 28, 2026
Apr 24, 2026Starks Daniel JDirectoraward2,286$0.00—7MApr 28, 2026
Apr 24, 2026Roman Michael FDirectoraward2,286$0.00—10,764Apr 28, 2026
Apr 24, 2026O'Grady MichaelDirectoraward2,286$0.00—7,603Apr 28, 2026
Apr 24, 2026McKinstry NancyDirectoraward2,286$0.00—41,010Apr 28, 2026
Apr 24, 2026McDew Darren WDirectoraward2,286$0.00—12,678Apr 28, 2026
Apr 24, 2026Kumbier MichelleDirectoraward2,286$0.00—18,000Apr 28, 2026
Apr 24, 2026Gonzalez Patricia PaolaDirectoraward2,286$0.00—9,205Apr 28, 2026
Apr 24, 2026Blount Sally E.Directoraward2,286$0.00—36,344Apr 28, 2026

Full insider history for Abbott Laboratories, or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
ABBOTT LABORATORIES, CIK 1800 on EDGAR
Extract generated
August 27, 2026
Withheld
5 line-years whose four quarters do not sum to the filed year: revenue FY2011, revenue FY2012, operating income FY2013, opex sga FY2013, pretax income FY2013
Repaired
4 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: operating income FY2011, pretax income FY2011, other income FY2015, other income FY2016
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, SalesRevenueNet
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: ShortTermInvestments
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt, LongTermDebtNoncurrent
Total liabilities: not filed
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: not filed
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividends, PaymentsOfDividendsCommonStock

The data

The statements on this page as files, generated August 27, 2026.

JSON file
/data/financials/ABT.json